Enfortumab Vedotin

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 740 publications

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. Reply.

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. Reply.

Journal: The New England journal of medicine

Published: June 17, 2026

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

Journal: The New England journal of medicine

Published: June 17, 2026

Enfortumab vedotin-induced cutaneous toxicities and their association with survival in urothelial carcinoma.

Enfortumab vedotin-induced cutaneous toxicities and their association with survival in urothelial carcinoma.

Journal: medRxiv : the preprint server for health sciences

Published: June 04, 2026

Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.

Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.

Journal: JAMA network open

Published: June 01, 2026

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

Journal: Future oncology (London, England)

Published: May 16, 2026

Real-world treatment patterns for metastatic urothelial cancer in 5 European countries: EVEREST 2.

Real-world treatment patterns for metastatic urothelial cancer in 5 European countries: EVEREST 2.

Journal: Future oncology (London, England)

Published: May 11, 2026

Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations.

Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 07, 2026

Re: Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med 2026;394:1257-1269.

Re: Christof Vulsteke, Nabil Adra, Pongwut Danchaivijitr, et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med 2026;394:1257-1269.

Journal: European urology

Published: April 27, 2026

Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective.

Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: April 14, 2026

New and Emerging Drug Reactions.

New and Emerging Drug Reactions.

Journal: Dermatologic clinics

Published: April 08, 2026

Precision medicine in bladder cancer: Redefining treatment paradigms through ADCs, immunotherapy, and molecular subtyping.

Precision medicine in bladder cancer: Redefining treatment paradigms through ADCs, immunotherapy, and molecular subtyping.

Journal: Critical reviews in oncology/hematology

Published: April 07, 2026

Optimized management of enfortumab vedotin-related dermatological toxicity.

Optimized management of enfortumab vedotin-related dermatological toxicity.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 06, 2026

Showing 1-12 of 740

Last Updated: 06/30/2026